Acer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACER, and when can generic versions of ACER drugs launch?
ACER has three approved drugs.
There are eleven US patents protecting ACER drugs.
There are one hundred and forty-seven patent family members on ACER drugs in thirty-five countries and seventy-three supplementary protection certificates in ten countries.
Drugs and US Patents for Acer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-004 | Dec 22, 2022 | RX | Yes | No | 11,202,767 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-001 | Dec 22, 2022 | RX | Yes | No | 11,154,521 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-001 | Mar 3, 2017 | DISCN | Yes | No | 7,799,761 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | RX | Yes | Yes | 8,784,882 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acerus Pharms | NOCTIVA | desmopressin acetate | SPRAY, METERED;NASAL | 201656-002 | Mar 3, 2017 | 7,579,321 | ⤷ Try a Trial |
Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,784,882 | ⤷ Try a Trial |
Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,574,622 | ⤷ Try a Trial |
Acerus | NATESTO | testosterone | GEL, METERED;NASAL | 205488-001 | May 28, 2014 | 8,877,230 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Acer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2010075266 | ⤷ Try a Trial |
Japan | 6389209 | ⤷ Try a Trial |
Russian Federation | 2006120468 | ⤷ Try a Trial |
Slovenia | 3429559 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1175904 | 2007C/048 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
0186405 | SPC/GB00/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
1713823 | 1490064-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
2380576 | 2020/043 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; NAT REGISTRATION NO/DATE: PA2103/003/001 20170602; FIRST REGISTRATION NO/DATE: SE/H/1547/001/DC 20160729 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.